Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Edwards Lifesciences Reports Third Quarter Results
October 25, 2016 4:15 PM EDTIRVINE, Calif., Oct. 25, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2016.
Third Quarter Highlights:
Sales grew 20.1% to $739.4 million; underlying1 sales were up 18.4% Global Transcatheter Heart Valve Therapy (THVT) sales grew 38.5% U.S. THVT sales were up 55.9% to $259.5 million GAAP EPS was $0.65, an increase of 20.4%; adjusted2 EPS grew 25.9% to $0.68 Reiterated... More